Items Tagged ‘major depressive disorder’
July 15, 2014
Genome-Wide Associations of Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations
By Center for Individualized Medicine 
Published in the British Journal of Clinical Pharmacology, a team of researchers from the Mayo Clinic, led by the director of the Center for Individualized Medicine’s Pharmacogenomics Program, Richard Weinshilboum, M.D., applied a genome-wide association study (GWAS) to identify genetic factors that contribute to variation in plasma concentrations of Citalopram (CT) or escitalopram (S-CT), and […]
Tags: center for individualized medicine, citalopram, DNA, DNA Sequencing, dna test, DNA Testing, escitalopram, gene sequencing, genetic, Genetics, genome, genome science
March 13, 2014
Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations: Genome-Wide Associations
A recently published article in the area of Pharmacogenomics set out to identify genetic factors in Citalopram (CT) and escitalopram (S-CT), which are among the most widely prescribed serotonin reuptake inhibitors (SSRIs) used to treat Major Depressive Disorder (MDD), that contribute to variation in plasma concentrations of CT or S-CT and their metabolites in MDD patients treated […]
Tags: citalopram, dna test, DNA Testing, escitalopram, gene sequencing, genome science, genome-wide association studies, genomic medicine, genomics, individualized medicine, major depressive disorder, personal genomics